ACAD Q1 2024 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$206M+73.8% YoY

Gross Profit

$183M88.8% margin

Operating Income

$15M7.4% margin

Net Income

$17M8.0% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

-10.9%

Cash Flow

Operating Cash Flow

$29M

Free Cash Flow

$29M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$855M

Total Liabilities

$391M

Stockholders' Equity

$464M

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$206M	$118M	+73.8%
Gross Profit	$183M	$117M	+56.6%
Operating Income	$15M	-$54M	+128.4%
Net Income	$17M	-$43M	+138.5%